Table 3. Pooled ORs with 95% CIs for the association between MNS16A and cancer risk by stratified analysis.
| Category | Genetic model | ORs (95%CI) | P a | P for heterogeneity | I2 | |
| Ethnicity | Caucasian | S vs. L | 1.16 (1.06–1.26) | 0.001 | 0.235 | 23.4% |
| (No. of study = 9) | LS vs. LL | 1.16 (1.05–1.28) | 0.003 | 0.689 | 0.00% | |
| SS vs. LL | 1.33 (1.15–1.54) | 0.000 | 0.383 | 6.20% | ||
| Dominant | 1.19 (1.09–1.31) | 0.000 | 0.696 | 0.00% | ||
| Recessive | 1.23 (1.07–1.42) | 0.003 | 0.322 | 13.5% | ||
| Asian | S vs. L | 1.08 (0.76–1.55) | 0.658 | 0.002 | 80.0% | |
| (No. of study = 4) | LS vs. LL | 1.10 (0.78–1.56) | 0.591 | 0.005 | 76.3% | |
| SS vs. LL | 1.13 (0.54–2.35) | 0.747 | 0.188 | 37.3% | ||
| Dominant | 1.10 (0.76–1.57) | 0.621 | 0.003 | 78.7% | ||
| Recessive | 1.12 (0.53–2.33) | 0.768 | 0.204 | 34.8% | ||
| Cancer type | Cerebral Cancer | S vs. L | 1.19 (1.10–1.30) | 0.000 | 0.503 | 0.00% |
| (No. of study = 5) | LS vs. LL | 1.17 (1.04–1.32) | 0.008 | 0.708 | 0.00% | |
| SS vs. LL | 1.42 (1.19–1.70) | 0.000 | 0.303 | 17.6% | ||
| Dominant | 1.22 (1.09–1.37) | 0.000 | 0.686 | 0.00% | ||
| Recessive | 1.32 (1.11–1.56) | 0.001 | 0.248 | 26.0% | ||
| Lung Cancer | S vs. L | 0.96 (0.62–1.49) | 0.842 | 0.066 | 63.3% | |
| (No. of study = 3) | LS vs. LL | 1.07 (0.84–1.37) | 0.571 | 0.379 | 0.00% | |
| SS vs. LL | 1.14 (0.51–2.57) | 0.744 | 0.180 | 41.7% | ||
| Dominant | 1.07 (0.81–1.42) | 0.627 | 0.315 | 13.4% | ||
| Recessive | 1.23 (0.56–2.73) | 0.609 | 0.229 | 32.2% | ||
| Breast Cancer | S vs. L | 1.31 (1.00–1.72) | 0.046 | 0.214 | 35.2% | |
| (No. of study = 2) | LS vs. LL | 1.52 (1.19–1.94) | 0.001 | 0.914 | 0.00% | |
| SS vs. LL | 1.12 (0.64–1.99) | 0.687 | 0.691 | 0.00% | ||
| Dominant | 1.46 (1.16–1.84) | 0.002 | 0.620 | 0.00% | ||
| Recessive | 0.97 (0.57–1.66) | 0.904 | 0.576 | 0.00% |
a
P value was calculated by the Z test.